| Added by | mollevi |
|---|---|
| Last modified by | standudu |
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer |
| Creator | Kato et al. |
| Author | Ken Kato |
| Author | Manish A. Shah |
| Author | Peter Enzinger |
| Author | Jaafar Bennouna |
| Author | Lin Shen |
| Author | Antoine Adenis |
| Author | Jong-Mu Sun |
| Author | Byoung Chul Cho |
| Author | Mustafa Özgüro?lu |
| Author | Takashi Kojima |
| Author | Vladimir Kostorov |
| Author | Cinta Hierro |
| Author | Ying Zhu |
| Author | Lee Anne McLean |
| Author | Sukrut Shah |
| Author | Toshihiko Doi |
| Abstract | BACKGROUND: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. AIM: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719. |
| Publication | Future Oncology (London, England) |
| Volume | 15 |
| Issue | 10 |
| Pages | 1057-1066 |
| Date | Apr 2019 |
| Journal Abbr | Future Oncol |
| Language | eng |
| DOI | 10.2217/fon-2018-0609 |
| ISSN | 1744-8301 |
| Short Title | KEYNOTE-590 |
| Library Catalog | PubMed |
| Extra | 00000 PMID: 30735435 |
| Tags | Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Double-Blind Method, Esophageal Neoplasms, esophagogastric junction cancer, Female, Fluorouracil, Follow-Up Studies, gastrointestinal/esophageal, Humans, Male, Middle Aged, PD-1, PD-L1, pembrolizumab, Prognosis, Research Design, squamous cell carcinoma of the esophagus, Survival Rate, Young Adult |
| Date Added | 2019/09/12 - 14:33:29 |
| Date Modified | 2019/09/13 - 10:20:27 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
